Evinacumab

Evinacumab Overview

Evinacumab is a first-in-class, targeted biologic medication developed for specialized cardiovascular and lipid management. It is a recombinant human IgG4 monoclonal antibody designed specifically to lower extremely high levels of low-density lipoprotein cholesterol (LDL-C) in patients with a rare, life-threatening genetic condition called Homozygous Familial Hypercholesterolemia (HoFH).

What Is Evinacumab and How Does It Work

Evinacumab acts as a novel Targeted Therapy for lipid metabolism. Standard cholesterol-lowering drugs like statins and PCSK9 inhibitors depend heavily on the presence of functional LDL receptors on liver cells to clear cholesterol from the blood. However, patients with HoFH inherit mutated, non-functional LDL receptors from both parents, rendering traditional therapies largely ineffective.

Evinacumab solves this clinical challenge by operating through an LDL-receptor-independent pathway:

• ANGPTL3 Inhibition: It binds directly to and inhibits angiopoietin-like protein 3 (ANGPTL3), a protein produced primarily in the liver that naturally suppresses two crucial lipid-clearing enzymes: lipoprotein lipase (LPL) and endothelial lipase (EL).
• Enzyme Disinhibition: By blocking ANGPTL3, Evinacumab unleashes LPL and EL activity.
• Rapid Lipid Clearance: The active enzymes rapidly accelerate the breakdown and clearance of Very Low-Density Lipoproteins (VLDL) before they can be converted into dangerous LDL cholesterol in the bloodstream.

This unique mechanism enables Evinacumab to dramatically reduce circulating LDL-C levels regardless of whether the patient possesses functional LDL receptors.

Is Evinacumab FDA Approved

Yes, Evinacumab was approved by the FDA in February 2021 under the brand name Evkeeza.The therapeutic indication was expanded to lower the age threshold for eligible pediatric patients.

What Is Evinacumab Used For

• Indicated as an adjunct (add-on) therapy alongside other lipid-lowering treatments (such as statins, ezetimibe, or apheresis) for adult and pediatric patients with Homozygous Familial Hypercholesterolemia (HoFH).
• Approved by the FDA for patients aged 1 year and older (and aged 6 months and older for EMA and Health Canada indications).

Note: The safety and effectiveness of Evinacumab have not been established in patients with other causes of high cholesterol outside of confirmed HoFH.

Before Taking Evinacumab: Contraindications and Precautions

Because Evinacumab is a targeted protein-based antibody, clinical precautions focus primarily on severe hypersensitivity reactions and potential risks during pregnancy.

Who Should Not Take Evinacumab

• Patients with a history of serious hypersensitivity or allergic reactions to Evinacumab or any of the inactive ingredients in the solution.

Evinacumab Pregnancy and Fertility

• Fetal Harm Risk: Based on animal reproduction studies, Evinacumab may cause fetal harm when administered to a pregnant woman.
• Females of reproductive potential must have a negative pregnancy test confirmed prior to initiating therapy and must use effective contraception during treatment and for at least 5 months following the final infusion.
• Nursing mothers should discuss the risks with their physician, as human IgG antibodies are known to pass into breast milk.

Tell Your Doctor Before Taking Evinacumab

• Disclose if you are pregnant, planning to become pregnant, or breastfeeding.
• Inform your medical team if you have a history of severe allergies or previous infusion-related reactions to biological drugs.
• Provide a complete list of all concurrent cholesterol-lowering medications and treatments, including the frequency of any lipoprotein apheresis procedures.

Evinacumab: Dosage and Administration

Evinacumab is administered strictly in a specialized clinical setting by qualified healthcare professionals.

Standard Evinacumab Dosing

• The recommended dosage for both adult and pediatric patients is 15 mg per kg of body weight.
• It is administered as a continuous intravenous infusion once every 4 weeks (monthly).

How Evinacumab Is Administered

• The medication is supplied as a single-dose concentrated solution that must be diluted in 0.9% Sodium Chloride or 5% Dextrose injection solution by a clinical pharmacist.
• It is infused intravenously over a duration of 60 minutes.
• It must never be administered as an intravenous push or bolus injection.

Evinacumab: Clinical Efficacy and Research

The approval of Evinacumab was driven by the landmark Phase 3 ELIPSE-HoFH trial. In this placebo-controlled study, patients with HoFH who were already receiving maximum tolerated doses of conventional lipid-lowering therapies were given monthly Evinacumab infusions. After 24 weeks, patients receiving Evinacumab achieved an average 49% reduction in LDL cholesterol levels from baseline compared to placebo. Crucially, the drug demonstrated nearly equal efficacy in patients with “receptor-negative” mutations who typically show zero response to other pharmaceutical options.

Evinacumab: Side Effects and Safety Profile

Evinacumab is generally well-tolerated, with most reported side effects classified as mild to moderate in severity.

Evinacumab Common Side Effects

• Nasopharyngitis (symptoms of a common cold, such as a runny nose or sore throat).
• Flu-like symptoms, including mild fever, chills, and muscle aches.
• Dizziness and generalized fatigue.
• Mild nausea or abdominal discomfort.
• Pain or discomfort in the arms, legs, or back.

Serious Evinacumab Adverse Events

• Anaphylaxis and Severe Hypersensitivity: Rare but severe allergic reactions during or shortly after the infusion, characterized by difficulty breathing, hives, swelling of the face or throat, and dangerous drops in blood pressure.
• Infusion-Related Reactions: Transient physical reactions during administration, including chest tightness, flushing, or rash.

Managing Evinacumab Side Effects

If signs of a severe allergic reaction or significant infusion response occur, the IV infusion must be stopped immediately, and appropriate emergency medical treatment (such as epinephrine or corticosteroids) must be initiated. Minor cold-like symptoms typically resolve on their own without stopping therapy.

Evinacumab: Interactions and What to Avoid

Because Evinacumab is a monoclonal antibody cleared through protein catabolism rather than cytochrome P450 enzymes in the liver, classic small-molecule drug interactions are unlikely.

Evinacumab Interactions

• Other Lipid Therapies: Evinacumab works synergistically with statins, ezetimibe, bile acid sequestrants, and PCSK9 inhibitors without adversely altering their blood concentrations.
• Lipoprotein Apheresis: When used alongside apheresis, the timing of the Evinacumab infusion should ideally be coordinated so it is administered after the apheresis session to avoid premature physical clearance of the antibody.

Evinacumab Food and Alcohol

• There are no known direct interactions with specific foods or alcohol. However, patients with HoFH are required to maintain a strict heart-healthy, low-fat diet.

Evinacumab: Missed Dose, Overdose and Storage

Because administration occurs in a hospital or specialized clinic, scheduling is closely managed by medical staff.

Missed Dose of Evinacumab

If an infusion appointment is missed, it should be rescheduled and administered as soon as possible. Thereafter, the monthly dosing schedule should be resumed based on the date of the newly administered dose.

Evinacumab Overdose and Emergency

Overdoses in clinical settings are extremely rare. In the event of an accidental higher dose, the patient will be monitored clinically for any exaggerated side effects or hypersensitivity reactions.

How To Store Evinacumab

Unopened vials must be kept refrigerated at 2°C to 8°C (36°F to 46°F) in their original carton to protect them from light. They must never be frozen or shaken vigorously.

Evinacumab: Patient Management and Monitoring

Ongoing clinical oversight ensures the medication continues to clear cholesterol safely without causing adverse systemic effects.

Tests Before Starting Evinacumab

• Baseline blood tests to measure total cholesterol, LDL-C, HDL-C, and triglycerides.
• Confirmation of a genetic or clinical diagnosis of Homozygous Familial Hypercholesterolemia.
• Serum pregnancy test for females of childbearing potential.

Monitoring During Evinacumab Treatment

• Routine lipid panel blood tests drawn periodically to assess the percentage reduction in LDL cholesterol.
• Continuous visual observation during the 60-minute infusion and for a brief post-infusion period to watch for signs of hypersensitivity.
• Regular monitoring of pregnancy status in female patients of childbearing age.

Evinacumab Do’s and Don’ts

• Do continue taking all of your other prescribed daily cholesterol medications (like statins) alongside your monthly Evinacumab infusions.
• Do maintain a strict, low-cholesterol diet as directed by your lipid specialist or cardiologist.
• Do inform your doctor immediately if you suspect you might be pregnant.
• Don’t stop receiving your monthly infusions simply because your blood test numbers improve; HoFH is a lifelong genetic condition that requires continuous management.

Frequently Asked Questions

References

• FDA Drugs@FDA Database: Evkeeza (Evinacumab-dgnb) Prescribing Information

• DrugBank Online: Evinacumab Pharmacological Profile (DB15354)

• European Medicines Agency (EMA): Evkeeza Product Information Guidelines

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at Liv Hospital or your local clinic before starting or stopping any medication.